SAN DIEGO — New guidelines for cutaneous melanoma have been issued by the National Comprehensive Cancer Network (NCCN), creating some new standards of practice that extend […]

SAN DIEGO — The investigative oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib shows promise in patients with moderate to severe hidradenitis suppurativa (HS), results from a […]

SAN DIEGO — In the clinical experience of Mio Nakamura, MD, MS, providing dermatologic care to patients with personality disorders requires a certain level of flexibility […]

A resolution to eliminate diversity efforts at the American Academy of Dermatology (AAD) has sparked fierce controversy on the eve of the group’s annual conference in […]

Sulfites, present in foods, drinks, pharmaceuticals, and personal care products, have been named the “Allergen of the Year” for 2024 by the American Contact Dermatitis Society […]

Only three of 13 biologics used to treat psoriasis were found cost-effective in the US market, according to a new analysis that used an approach to […]

TOPLINE: The odds of having cognitive impairment may be increased among children with atopic dermatitis (AD), primarily among those with neurodevelopmental disorders, such as attention-deficit/hyperactivity disorder […]

The Food and Drug Administration has approved the hyaluronic acid dermal filler Juvéderm Voluma XC for injection in the temple region to improve moderate to severe temple […]

The Food and Drug Administration (FDA) has approved letibotulinumtoxinA-wlbg, an injectable neurotoxin long used in South Korea for the treatment of moderate to severe glabellar (frown) […]